

AN 107:223151 CA

TI Progress in the testing of surfactant-stabilized neutral insulin (Hoe 21 PH) in various dispensing systems

AU Grau, U.

SO Life Support Systems (1986), 3(Suppl. 1, Proc. - Eur. Soc. Artif. Organs, Annu. Meet., 12th, 1985), 551-5

CODEN: LSSYD6; ISSN: 0261-989X

AB To increase insulin stability in implantable pumps Hoe 21 PH, a neutral insulin prepn. stabilized against denaturation on hydrophobic surfaces by \*\*\*Genapol\*\*\*, was examd. In vitro tests indicated an improvement in performance under peristaltic pump conditions while maintaining quality and stability of Hoe 21 PH.

\*\*\*Genapol\*\*\* insulin stabilized

\* \* \* \* \*

L10 ANSWER 1 OF 1 MEDLINE on STN

AN 2001017670 MEDLINE

DN 20467183 PubMed ID: 11011223

TI Possible activation of auto-immune thyroiditis from continuous subcutaneous infusion of \*\*\*genapol\*\*\*-containing insulin.

AU Chantelau E

CS Diabetesambulanz MNR-Klinik, Heinrich-Heine-Universitat Dusseldorf  
Postfach 10 10 07 D-40001 Dusseldorf.

SO DIABETES AND METABOLISM, (2000 Sep) 26 (4) 304-6.

Journal code: 9607599. ISSN: 1262-3636.

AB A case of a type 1 diabetic woman with auto-immune thyroiditis is reported, in whom repeated exposure to insulin containing \*\*\*Genapol\*\*\* (R) (polyethylen-polypropylenglycol) over 3 years reproducibly parallels with an increase of serum TSH (thyroid-stimulating hormone) above the normal limit. Previously, adverse effects of \*\*\*Genapol\*\*\* (R) insulin

Serial No. 09/344,676  
Art Unit 1653

-17-

\*\*\*\*\*

L12 ANSWER 2 OF 4 MEDLINE on STN

AN 2001189321 MEDLINE

DN 21174927 PubMed ID: 11280713

TI High antigenicity of intraperitoneal insulin infusion via implantable  
devices: preliminary rat studies.

AU Jeandidier N; Boullu S; Delatte E; Sapin R; Steibel J; Meyer P; Uhl C;  
Pinget M

SO HORMONE AND METABOLIC RESEARCH, (2001 Jan) 33 (1) 34-8.  
Journal code: 0177722; ISSN: 0018-5043.

AB Intraperitoneal \*\*\*insulin\*\*\* infusion of \*\*\*Genapol\*\*\* stabilized  
\*\*\*insulin\*\*\* via implantable devices significantly improves diabetes

\*\*\*\*\*

AN 91223732 MEDLINE

DN 91223732 PubMed ID: 2091873

TI Stabilized human insulin prevents catheter occlusion during continuous  
subcutaneous insulin infusion.

AU Walter H M; Timmler R; Mehnert H

SO DIABETES RESEARCH, (1990 Feb) 13 (2) 75-7.

Journal code: 8502339. ISSN: 0265-5985.

AB Obstruction of infusion sets is a major cause of metabolic deterioration or even ketoacidosis during continuous subcutaneous \*\*\*insulin\*\*\* infusion (CSII). 21 type I, CSII-treated patients were studied in a prospective, randomized cross over design during two periods of three months to assess the effects of \*\*\*Genapol\*\*\* stabilized human \*\*\*insulin\*\*\* (HOE 21 PH H-TRONIN) on obstruction frequency of PVC

\* \* \* \* \*

L12 ANSWER 4 OF 4 MEDLINE on STN

AN 85028172 MEDLINE

DN 85028172 PubMed ID: 6386584

TI Stabilisation of dissolved proteins against denaturation at hydrophobic interfaces.

AU Thurow H; Geisen K

SO DIABETOLOGIA, (1984 Aug) 27 (2) 212-8.

Journal code: 0006777. ISSN: 0012-186X.

AB Studies with \*\*\*insulin\*\*\* delivery devices have shown that denaturation of dissolved proteins at hydrophobic interfaces is a basic obstacle to long-term \*\*\*insulin\*\*\* stability in pumps. This study shows that polypropylene glycol/polyethylene glycol block polymers prevent both the adsorption of dissolved proteins to hydrophobic interfaces and the resultant aggregation. At a concentration of 0.001% (w/v), the block polymer \*\*\*Genapol\*\*\* PF-10 stabilises \*\*\*insulin\*\*\* solutions over a wide range of concentrations. \*\*\*Insulin\*\*\* solutions thus

\* \* \* \* \*

AN 91223732 MEDLINE

DN 91223732 PubMed ID: 2091873

TI Stabilized human insulin prevents catheter occlusion during continuous  
subcutaneous insulin infusion.

AU Walter H M; Timmler R; Mehnert H

SO DIABETES RESEARCH, (1990 Feb) 13 (2) 75-7.

Journal code: 8502339. ISSN: 0265-5985.

AB Obstruction of infusion sets is a major cause of metabolic deterioration  
or even ketoacidosis during continuous subcutaneous \*\*\*insulin\*\*\*  
infusion (CSII). 21 type I, CSII-treated patients were studied in a  
prospective, randomized cross over design during two periods of three  
months to assess the effects of \*\*\*Genapol\*\*\* stabilized human  
\*\*\*insulin\*\*\* (HOE 21 PH H-TRONIN) on obstruction frequency of PVC